Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 15/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CTRC | Q99895 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4452584 | 0.92 | KLK5 (0.50) | CMA1KMT2AATMKLK5ACE | |
| SCHEMBL7352711 | 0.90 | ACE (0.53) | CMA1KMT2AKLK5ACE | |
| SCHEMBL7348146 | 0.89 | MAPK1 (0.51) | CMA1KMT2AKLK5ACE | |
| SCHEMBL7348914 | 0.85 | CMA1 (0.49) | CMA1KMT2AMEN1ATMKLK5 | |
| SCHEMBL7355589 | 0.83 | ACE (0.46) | CMA1KMT2AKLK5ACE | |
| SCHEMBL7354574 | 0.82 | MEN1 (0.47) | CMA1KMT2AMEN1KLK5ACE | |
| SCHEMBL7357094 | 0.82 | SCN9A (0.46) | CMA1KMT2AKLK5ACE | |
| SCHEMBL7350216 | 0.80 | KMT2A (0.39) | CMA1KMT2AMEN1ATMKLK5 | |
| SCHEMBL4455011 | 0.78 | CMA1 (0.73) | CMA1KMT2AACECTRC | |
| Hydrochloric Acid SCHEMBL4447405 | 0.77 | KMT2A (0.43) | CMA1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20040086537-A1 | Prophylactic or threapeutic composition for ocular circulation disorders | INOUE JUN (JP) | 2004-05-06 | — | — | US | disclosed |
| EP-1224945-A1 | TENSION-RELIEVING AGENTS FOR CILIARY MUSCLE | Senju Pharmaceutical Co., Ltd. (JP) | 2002-07-24 | — | — | EP | disclosed |
| EP-1112749-A2 | PREVENTIVES OR REMEDIES FOR EYE CIRCULATORY FAILURE | Senju Pharmaceutical Co., Ltd. (JP) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040086537-A1 | Prophylactic or threapeutic composition for ocular circulation disorders | CMA1, THOP1, TPSAB1 | CMA1 1/4885KMT2A 4655/4885MEN1 3448/4885 |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | PTGIS, PTGIR, GRPR | CMA1 313/4885KMT2A 4822/4885MEN1 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.